The following terms were used to search PubMed, Medline, and the Web of Science for pertinent articles: “hyperparathyroidism”, “primary hyperparathyroidism”, “secondary hyperparathyroidism”, “tertiary hyperparathyroidism”, “chronic kidney disease”, “vitamin D deficiency”, and “familial benign hypercalcaemic hypocalciuria”. There was no restriction on language, and all years were searched. A computer link program was used to exclude duplicate articles, and linked articles were searched for
SeminarHyperparathyroidism
Introduction
Ionised calcium in plasma is closely regulated and ranges from 1·1 mmol/L to 1·3 mmol/L (calcium adjusted for albumin 2·2–2·6 mmol/L). Precise control of ionised calcium is needed to ensure optimum function of physiological processes, particularly cell signalling, neural function, muscular function, and bone metabolism. Pivotal in regulation of ionised calcium is secretion of parathyroid hormone from the parathyroid glands, usually located in the neck, which respond to changes in circulating ionised calcium via the calcium-sensing receptor (CaSR) located on the surface of the chief cells.1 Parathyroid hormone has a major biological function in maintaining ionised calcium and phosphate within the reference range by stimulating specific receptor-mediated responses in cells throughout the body. If a decrease in circulating ionised calcium occurs, parathyroid hormone increases and has three major functions that help to restore a normal circulating concentration (figure 1): receptor-mediated tubular reabsorption of calcium (kidney); stimulation of osteoclast resorption to release skeletal calcium (bone); and increasing activity of renal 1 hydroxylase, resulting in production of 1,25-dihyroxyvitamin D and increasing calcium absorption (bowel). The increase in calcium in response to these effects mediated by parathyroid hormone acts via a classic endocrine feedback loop on the CaSR, decreasing secretion of parathyroid hormone.
Components in this regulatory system can cause excessive secretion of parathyroid hormone and hyperparathyroidism. Primary hyperparathyroidism can occur when one or more parathyroid glands secrete excess parathyroid hormone; secondary hyperparathyroidism arises when increased secretion of this hormone is a response to lowered ionised calcium as a result of kidney, liver, or bowel disease; and in tertiary hyperparathyroidism, a state of autonomous secretion of parathyroid hormone usually occurs as a result of longstanding chronic kidney disease.
In addition to parathyroid hormone, other major factors maintaining normocalcaemia are 1,25-dihydroxyvitamin D, which promotes calcium and phosphate absorption via the bowel; and calcitonin, produced by C cells of the thyroid, which acts on osteclasts, inhibiting their activity and reducing the release of calcium and phosphate from bone (figure 1).
Section snippets
Definition, pathology, cause, and epidemiology
In primary hyperparathyroidism, in the absence of a known or recognised stimulus, one or more of the four parathyroid glands secrete excess parathyroid hormone, resulting in hypercalcaemia (intrinsic abnormal change). Single gland adenoma is the most common cause (75–85%), multigland adenoma arises in a substantial proportion (two glands in 2–12% of cases, three glands in <1–2%, and four or more in <1–15%), and parathyroid carcinoma is rare (∼1%). Lower pole adenomas (in relation to the
Definition and causes
Secondary hyperparathyroidism is the result of failure of one or more components of the calcium homoeostatic mechanisms described previously (extrinsic abnormal change). When plasma ionised calcium decreases, the CaSR responds by increasing secretion of parathyroid hormone, resulting in a compensatory mechanism to restore normal function. Under normal circumstances, there is a transient state of relative or absolute secondary hyperparathyroidism. When the parathyroid hormone cannot correct the
Tertiary hyperparathyroidism
Although authors debate the existence of tertiary hyperparathyroidism, most believe that it represents a state of autonomous function of parathyroid tissue (intrinsic abnormal change) that is characterised by hypercalcaemic hyperparathyroidism. It is usually the outcome of longstanding secondary hyperparathyroidism and is characterised by a lack of suppression of parathyroid hormone by increasing calcium or vitamin D analogues. CaSR underexpression can be seen resulting in an increase in
Search strategy and selection criteria
References (151)
- et al.
Incidence and location of ectopic abnormal parathyroid glands
Am J Surg
(2006) - et al.
Primary hyperparathyroidism: changes in the pattern of clinical presentation
Lancet
(1980) - et al.
Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism
Cell
(1993) Diseases associated with the extracellular calcium-sensing receptor
Cell Calcium
(2004)- et al.
Prospective evaluation of sestamibi scan, ultrasonography, and rapid PTH to predict the success of limited exploration for sporadic primary hyperparathyroidism
Surgery
(2004) - et al.
Primary hyperparathyroidism: effect of parathyroidectomy on regional bone mineral density in Danish patients: a three-year follow-up study
Bone
(1999) - et al.
Time course of regression of left ventricular hypertrophy after successful parathyroidectomy
Surgery
(1997) - et al.
Psychologic symptoms before and after parathyroid surgery
Am J Med
(1994) - et al.
Relationship between serum 25-hydroxyvitamin D and bone resorption markers in vitamin D insufficiency
Bone
(2002) - et al.
Redefining vitamin D insufficiency
Lancet
(1998)
The calcium-sensing receptor in normal physiology and pathophysiology: a review
Crit Rev Clin Lab Sci
Therapeutic radiation and hyperparathyroidism. A case-control study in Rochester, Minn
Arch Intern Med
Hyperparathyroidism among atomic bomb survivors in Hiroshima
Radiat Res
Dose-response relationships for radiation-induced hyperparathyroidism
J Clin Endocrinol Metab
Risk of parathyroid adenomas in patients with thyrotoxicosis exposed to radioactive iodine
Acta Oncol
Clinical findings in patients with hypercalcaemia. A final investigation based on biochemical screening
Acta Med Scand
The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965–1992
Ann Intern Med
The epidemiology of primary hyperparathyroidism in North America
J Bone Miner Res
Epidemiology of primary hyperparathyroidism in Europe
J Bone Miner Res
Asymptomatic primary hyperparathyroidism: new issues and new questions—bridging the past with the future
J Bone Miner Res
Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention
J Bone Miner Res
A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery
N Engl J Med
The changing presentation of hyperparathyroidism over 3 decades
Arch Surg
Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values
J Clin Endocrinol Metab
Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function
J Bone Miner Res
Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays
Clin Chem
Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism
J Clin Endocrinol Metab
Assessment of parathyroid function in clinical practice: which parathyroid hormone assay is better?
Clin Chem
Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism
Clin Chem
Familial hypocalciuric hypercalcemia: recognition among patients referred after unsuccessful parathyroid exploration
Ann Intern Med
Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review
Ann Clin Biochem
The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds
Med (Baltimore)
Bone mineral density in patients with familial hypocalciuric hypercalcaemia (FHH)
Eur J Surg
Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenetic studies in 21 families
Ann Intern Med
Familial hypocalciuric hypercalcaemia and acute pancreatitis
BMJ
Calcium infusion suggests a “set-point” abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism
J Clin Endocrinol Metab
Familial hypocalciuric hypercalcaemia: evidence for continued enhanced renal tubular reabsorption of calcium following total parathyroidectomy
Acta Endocrinol (Copenh)
Familial benign hypocalciuric hypercalcaemia
J Bone Miner Res
The value of 99mTc-sestamibi SPECT/CT over conventional SPECT in the evaluation of parathyroid adenomas or hyperplasia
J Nucl Med
Limitations of technetium 99m sestamibi scintigraphic localization for primary hyperparathyroidism associated with multiglandular disease
Am Surg
Intraoperative measurement of parathyroid hormone in the surgical management of hyperparathyroidism
Surgery
Lateralization of parathyroid adenomas by intra-operative parathormone estimation
J R Coll Surg Edinb
Evaluation of the performance and clinical impact of a rapid intraoperative parathyroid hormone assay in conjunction with preoperative imaging and concise parathyroidectomy
Clin Chem
Primary hyperparathyroidism surgical management since the introduction of minimally invasive parathyroidectomy: Mayo Clinic experience
Arch Surg
The management of primary hyperparathyroidism
Clin Endocrinol (Oxf)
Profile of a clinical practice: thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons
J Clin Endocrinol Metab
Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism
J Clin Endocrinol Metab
Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism
J Clin Endocrinol Metab
Primary hyperparathyroidism and the risk of fracture: a population-based study
J Bone Miner Res
Increased fracture risk in hypercalcemia. Bone mineral content measured in hyperparathyroidism
Acta Orthop Scand
Cited by (768)
Testing for Primary Hyperparathyroidism in 17,491 Patients With Hypercalcemia
2024, Journal of Surgical ResearchOutcomes of subtotal parathyroidectomy for renal hyperparathyroidism
2024, Surgery (United States)Secondary Hyperparathyroidism
2024, Otolaryngologic Clinics of North AmericaBilateral exploration in primary hyperparathyroidism: Double adenoma distribution and biochemical patterns over two decades
2024, American Journal of SurgeryDiagnosis and management of primary hyperparathyroidism during pregnancy: A systematic review and a longitudinal case study
2023, Gynecologie Obstetrique Fertilite et SenologieTreatment of Secondary Hyperparathyroidism and Posttransplant Tertiary Hyperparathyroidism
2023, Journal of Surgical Research